Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor Jan 10, 2018
Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT Nov 21, 2017
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 Nov 14, 2017
Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors Nov 1, 2017
Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial Oct 18, 2017
